Barbara Lawrenz, M.D.,Ph.D.

IVF Specialist at IVI UAE

IVI UAE

Contact info:
Barbara Lawrenz, M.D.,Ph.D.

Biography

Dr. Barbara Lawrenz graduated from medical school in Berlin and Giessen, Germany, and was a resident in gynecology and obstetrics at the hospital in Reutlingen, Germany, a teaching-hospital of the university Tuebingen, Germany.

After her residency in Obstetrics and Gynecology (“Facharzt“) she worked as a senior physician in different hospitals in leadership positions before joining the Women´s University Hospital in Tuebingen, Germany. There, she received additional sub-speciality training in Perinatal Medicine and Reproductive Endocrinology and Infertility. From 2007 until 2013 she was the Director of the IVF-unit of the Women’s University Hospital in Tuebingen, Germany. During this time, she had a special focus on “fertility preservation before cytotoxic therapy in women with malignant diseases“ and on “pregnancy after breast cancer“.

She was a member of the steering committee of the network “FertiPROTEKT“, a network which is specialised on the collection of data regarding fertility preservation counseling and treatment and the optimization of fertility preservation treatments. This network comprises university-based and private IVF-centers in Germany, Austria and Switzerland.

With her Habilitation thesis: “Fertility preservation before cytotoxic therapy in young girls, adolescents and premenopausal women“, she obtained the designation “lecturer“ (“Privatdozentin”) and the teaching license of the University of Tuebingen, Germany, for Gynecology and Obstetrics. She authored or co-authored 35 peer-reviewed articles in international journals and additional numerous articles in German journals.
Since 2013 she is working as an IVF-specialist in Abu Dhabi, UAE, and she joined IVI Middle East Fertility Clinic in Abu Dhabi in 2015. Her special focus is now on luteolysis and luteal phase support in IVF-treatments.


Read more

Education and Training

M.D. (1991)
Obstetrics and Gynecology Specialist (1995)
Sub-specialization in Maternal Fetal Medicine (2004)
Sub-specialization in Reproductive Endcrinologyt and Infrtility (2007)
Certificate for University Teaching and Learning in Medicine (2011)
Member of the steering committee of the network FertiPROTEKT (2011-2013)
Habilitation thesis: Fertility preservation before cytotoxic therapy in young girls, adolescents and premenopausal women. Obtaining the designation lecturer (“Privatdozentin”); Teaching license of the university of Tuebingen for Obstetrics and Gynecology (2012)

Publications


  • GnRHa trigger and luteal coasting – A new approach for the OHSS high-risk patient?
    Lawrenz B, Humaidan P, Kol S, Fatemi HM.
    RBMonline accepted for publication, 2017.

  • Individual luteolysis post GnRH-agonist-trigger in GnRH-antagonist protocols.
    Lawrenz B, Ruiz F, Engelmann N, Fatemi HM.
    Gynecol Endocrinol, 33(4):261-264, 2017.

  • Impact of gonadotropin type on progesterone elevation during ovarian stimulation in GnRH antagonist cycles.
    Lawrenz B, Beligotti F, Engelmann N, Gates D, Fatemi HM.
    Hum Reprod, 31(11):2554-2560, 2016.


  • Characteristics and attitudes of women in relation to chosen fertility preservation techniques: a prospective, multicenter questionnaire-based study with 144 participants.
    von Wolff M, Giesecke D, Germeyer A, Lawrenz B, Henes M, Nawroth F, Friebel S, Rohde A, Giesecke P, Denschlag D.
    Eur J Obstet Gynecol Reprod Biol, 201:12-7, 2016.

  • The effects of cancer therapy on women's fertility: what do we know now?
    Lawrenz B, Mahajan N, Fatemi HM.
    Future Oncol, 12(14):1721-9,2016.

  • Absence of luteal phase defect and spontaneous pregnancy in IVF patients despite GnRH-agonist trigger and "freeze all policy" without luteal phase support: a report of four cases.
    Gurbuz AS, Deveer R, Ozcimen N, Ozcimen EE, Lawrenz B, Banker M, Garcia-Velasco JA, Fatemi HM.
    Gynecol Endocrinol, 32(1):18-20, 2016.

  • Ovarian reserve alterations in premenopausal women with chronic inflammatory rheumatic diseases: impact of rheumatoid arthritis, Behçet's disease and spondyloarthritis on anti-Müllerian hormone levels.
    Henes M, Froeschlin J, Taran FA, Brucker S, Rall KK, Xenitidis T, Igney-Oertel A, Lawrenz B, Henes JC.
    Rheumatology (Oxford) 54(9):1709-12, 2015.

  • Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicenter trial with a minimization randomization scheme.
    Schleussner E, Kamin G, Seliger G, Rogenhofer N, Ebner S, Toth B, Schenk M, Henes M, Bohlmann MK, Fischer T, Brosteanu O, Bauersachs R, Petroff D; ETHIG II group. (Collaborators: Bauersachs R, Beuter-Winkler P, Bohlmann MK, Brosteanu O, Brückmann A, Dudenhausen J, Ebner S, Fischer T, Grüβner S, Henes M, Illing R, Kamin G, Kemkes-Matthes B, Lachmann R, Lawrenz B, Neuhaus P, Nitzsche K, Petroff D, Rogenhofer N, Scheler C, Schenk M, Schleussner E, Seeger S, Seeliger C, Seliger G, Thaler C, Toth B.).
    Ann Intern Med, 162(9):601-9, 2015.

  • Possibilities of fertility preservation in young patients with ovarian cancer.
    Henes M, Neis F, Krämer B, Walter C, Brucker S, Von Wolff M, Rothmund R, Lawrenz B, Rall K.
    Anticancer Res, 34(7):3851-4, 2014.

  • Anti-mullerian hormone deficiency in girls with congenital multiple pituitary hormone deficiency.
    Deubzer B, Weber K, Lawrenz B, Schweizer R, Binder G.
    J Clin Endocrinol Metab, 99(6):E1045-9, 2014.

  • High capacity for leukotriene biosynthesis in peripheral blood during pregnancy.
    Schaible AM, Koeberle A, Northoff H, Lawrenz B, Weinigel C, Barz D, Werz O, Pergola C.
    Prostaglandins Leukot Essent Fatty Acids, 89(4):245-55, 2013.

  • Reduced pretreatment ovarian reserve in premenopausal female patients with Hodgkin lymphoma or non-Hodgkin-lymphoma--evaluation by using antimüllerian hormone and retrieved oocytes.
    Lawrenz B, Fehm T, von Wolff M, Soekler M, Huebner S, Henes J, Henes M; Centers of FertiPROTEKT Network.
    Fertil Steril, 98(1):141-4, 2012.

  • Fertility preservation in women with vasculitis: experiences from the FertiPROTEKT network.
    Henes JC, Henes M, von Wolff M, Schmalzing M, Kötter I, Lawrenz B.
    Clin Exp Rheumatol, 30(1 Suppl 70):S53-6, 2012.

  • Fertility preservation methods in young women with systemic lupus erythematosus prior to cytotoxic therapy: experiences from the FertiPROTEKT network.
    Henes M, Henes JC, Neunhoeffer E, Von Wolff M, Schmalzing M, Kötter I, Lawrenz B. Lupus, 21(9):953-8. 2012.

  • Pregnancy after successful cancer treatment: what needs to be considered?
    Lawrenz B, Henes M, Neunhoeffer E, Fehm T, Huebner S, Kanz L, Marini P, Mayer F. Onkologie, 35(3):128-32, 2012.

  • The young cancer patient: psychosocial problems and concepts in rehabilitation.
    Beraldi A, Brathuhn S, Heussner P, König V, Lawrenz B.
    Onkologie, 34 Suppl 5:17-23, 2011.

  • Fertility preservation in prepubertal girls prior to chemotherapy and radiotherapy--review of the literature.
    Lawrenz B, Rothmund R, Neunhoeffer E, Huebner S, Henes M.
    J Pediatr Adolesc Gynecol, 25(5):284-8, 2012.

  • Lower extremity compartment syndrome after laparoscopic radical hysterectomy: brief report of an unusual complication of laparoscopic positioning requirements.
    Lawrenz B, Kraemer B, Wallwiener D, Witte M, Fehm T, Becker S.
    J Minim Invasive Gynecol, 18(4):531-3, 2011.

  • Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: evaluation by using anti-Muellerian hormone.
    Lawrenz B, Henes J, Henes M, Neunhoeffer E, Schmalzing M, Fehm T, Kïtter I.
    Lupus, 20(11):1193-7, 2011.

  • Fertility preservation in girls and adolescents before chemotherapy and radiation - review of the literature.
    Lawrenz B, Henes M, Neunhoeffer E, Fehm T, Lang P, Schwarze CP.
    Klin Padiatr, 223(3):126-30, 2011.

  • Fertility preservation in women--a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin's lymphoma and borderline ovarian tumours by the fertility preservation network FertiPROTEKT.
    von Wolff M, Montag M, Dittrich R, Denschlag D, Nawroth F, Lawrenz B.
    Arch Gynecol Obstet, 284(2):427-35, 2011.

  • Fertility conservation in breast cancer patients.
    Lawrenz B, Henes M, Neunhoeffer E, Kraemer B, Fehm T.
    Womens Health (Lond). 7(2):203-12, 2011.

  • Fertility preservation in young female lymphoma patients: review of available options and initial experiences with their implementation in clinical routine.
    Lawrenz B, Fehm T, Neunhoeffer E, Krämer B, Soekler M, Kanz L, Henes M, Mayer F. Onkologie, 34(3):88-93, 2011.

  • Fertility preservation for young patients with autoimmune diseases and the need for cytotoxic treatment. Clinical experiences from interdisciplinary consultation.
    Henes M, Henes JC, Schmalzing M, Neunhoeffer E, Rothmund R, Kötter I, Lawrenz B. Z Rheumatol, 70(2):146-53, 2011.

  • Pregnancy after breast cancer: case report and review of the literature.
    Lawrenz B, Banys M, Henes M, Neunhoeffer E, Grischke EM, Fehm T.
    Arch Gynecol Obstet, 283(4):837-43, 2011.

  • Fertility preservation in >1,000 patients: patient's characteristics, spectrum, efficacy and risks of applied preservation techniques.
    Lawrenz B, Jauckus J, Kupka MS, Strowitzki T, von Wolff M.
    Arch Gynecol Obstet, 283(3):651-6, 2011.

  • Improving fertility preservation in cancer: ovarian tissue cryobanking followed by ovarian stimulation can be efficiently combined.
    Huober-Zeeb C, Lawrenz B, Popovici RM, Strowitzki T, Germeyer A, Stute P, von Wolff M.
    Fertil Steril, 95(1):342-4, 2011.

  • Efficacy and safety of ovarian stimulation before chemotherapy in 205 cases.
    Lawrenz B, Jauckus J, Kupka M, Strowitzki T, von Wolff M.
    Fertil Steril, 94(7):2871-3, 2010.

  • Management of fertility preservation in young breast cancer patients in a large breast cancer centre.
    Lawrenz B, Neunhoeffer E, Henes M, Lessmann-Bechle S, Krämer B, Fehm T.
    Arch Gynecol Obstet, 282(5):547-51, 2010.

  • Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase.
    von Wolff M, Thaler CJ, Frambach T, Zeeb C, Lawrenz B, Popovici RM, Strowitzki T. Fertil Steril, 92(4):1360-5, 2009.

  • ERK-mediated regulation of leukotriene biosynthesis by androgens: a molecular basis for gender differences in inflammation and asthma.
    Pergola C, Dodt G, Rossi A, Neunhoeffer E, Lawrenz B, Northoff H, Samuelsson B, Rådmark O, Sautebin L, Werz O.
    Proc Natl Acad Sci U S A, 105(50):19881-6, 2008.


Publications in German Journals:



  • Sonne, Vitamin D und Fertilität.
    Lawrenz B, Fatemi HM.
    Gynäkologische Endokrinologie, 3:206-207, 2015.

  • Schwangerschaft nach Mammakarzinom.
    Lawrenz B, Grischke EM, Fehm T.
    Frauenheilkunde up2date 2011.

  • Der junge Krebspatient: Psychosoziale Probleme und Konzepte der Rehabilitation.
    Beraldi A, Brathuhn S, Heußner P, König V, Lawrenz B.
    Onkologie 34(suppl 5):17-23, 2011.

  • Borchmann P, Heußner P, Hilgendorf I, Katalinic A, Lawrenz B, Neubauer A, Willenbacher W, Wörmann B (authors in alphabetical order). Onkopedia 2011: Heranwachsende und junge Erwachsene (AYA, Adolescents and Young Adults) http://www.dgho-onkopedia.de/onkopedia/leitlinien/heranwachsende-und-junge-erwachsene-aya
    Therapieoptionen der Endometriose.
    Neunhoeffer E, Lawrenz B.
    Arzneimitteltherapie, 29:35-41, 2011.

  • Mammkarzinom und Schwangerschaft: Diagnostik, Therapie, Einfluss auf Fertilität und weitere Schwangerschaften.
    Grischke EM, Lawrenz B, Fehm T, Hoopmann M, Abele H, Kagan KO.
    Geburtshilfe und Frauenheilkunde, 70:1024-7, 2010.

  • Fertilitätsprotektion bei Frauen.
    Von Wolff M, Montag M, Dittrich R, Denschlag D, Nawroth F, Lawrenz B.
    Geburtshilfe und Frauenheilkunde, 70:R85-R100, 2010.

  • FertiPROTEKT-Netzwerk für fertilitätsprotektive Maßnahmen bei Chemo- und Strahlentherapie.
    Lawrenz B, von Wolff M.
    Journal für Reproduktionsmedizin und Endokrinologie, 7:147-50, 2010.

  • Fertilitätserhalt bei Krebs.
    Lawrenz B, von Wolff M, Neunhoeffer E, Fehm T, Mayer F.
    Tumordiagnostik und Therapie, 31:246, 2010.

  • Vorgehen bei Adnextorsion.
    Lawrenz B.
    Chirurgische Praxis 72:590, 2010.

  • Fertilitätsprotektion aktuell.
    Lawrenz B, Henes M, Neunhoeffer E, Fehm T, von Wolff M.
    Geburtshilfe und Frauenheilkunde, 70:325-7, 2010.

  • Therapie des polyzystischen Ovarsyndroms (PCOS).
    Henes M, Lessmann-Bechle S, Becker S, Lawrenz B.
    Arzneimitteltherapie, 27:191-7, 2009.

  • Vorgehen bei Adnextorsion.
    Lawrenz B.
    Gynäkologische Praxis2009;33:678.

  • Fertilitätserhalt vor Chemotherapie - was ist heute möglich?
    Lawrenz B, Fehm T, Henes M, von Wolff M.
    Frauenheilkunde up2date, 2:80-4, 2009.

  • Kinderwunsch – wie lange?
    Lawrenz B, Lessmann-Bechle S, Neunhoeffer E, Henes M.
    Geburtshilfe und Frauenheilkunde, 69:1112-4, 2009.

  • Fertilitäterhaltende Maßnahmen: Der Beginn der ovariellen Stimulation zur Gewinnung von Oozyten ist in der Lutealphase möglich.
    Lawrenz B, Thaler C, Frambach T, Zeeb C, Popovici RM, Strowitzki T, von Wolff M. Geburtshilfe und Frauenheilkunde, 69:420-2, 2009.

  • Adipositas und Sterilität.
    Lawrenz B, Wallwiener D.
    Pharma Focus Gynäkologie, 3:34-9, 2008.

  • Diagnostik und Therapie der Sterilität.
    Lawrenz B, Neunhoeffer E.
    Frauenheilkunde up2date, 2:155-71, 2008.

  • Syndrom der polyzystischen Ovarien (PCOS), Insulinresistenz und Sterilität bei adipösen Frauen.
    Lawrenz B, Neunhoeffer E.
    Geburtshilfe und Frauenheilkunde, 68:1106-8, 2008.

  • Chemotherapie und Fertilitätserhalt – was ist möglich?
    Lawrenz B, Binder H, Zeeb C, von Wolff M, Fehm T.
    Geburtshilfe und Frauenheilkunde, 67:490-2, 2007.


Read more
Close Menu